Ogino I, Kitamura T, Okajima H, Matsubara S
Department of Radiology, Yokohama City University, Yokohama, Japan.
Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):881-7. doi: 10.1016/s0360-3016(97)00924-3.
To assess the effectiveness of high-dose rate intracavitary brachytherapy (HDR-ICR) in patients with grade 3 cervical intraepithelial neoplasia (CIN-3) and grade 3 vaginal intraepithelial neoplasia (VAIN-3).
This was a retrospective analysis in 20 patients with CIN-3 (n = 14) or VAIN-3 (n = 6), average age 61.9 years, managed with HDR-ICR at Kanagawa Cancer Center. Two patients with CIN-3 with microinvasive foci and 11 other patients with CIN-3 were treated with HDR-ICR for cervical lesions. Six patients with CIN-3 after hysterectomy received HDR-ICR for recurrent or residual VAIN-3 lesions. One patient received radiation therapy for both CIN-3 and VAIN-3 lesions. All these patients but one were postmenopausal.
Seventeen patients were treated with HDR-ICR alone, and three with combined external radiation therapy. The dose was calculated at Point A located 2 cm superior to the external os and 2 cm lateral to the axis of the intrauterine tube for intact uterus. For lesions of the vaginal stump, the dose was calculated at a point 1 cm superior to the vaginal apex or 1 cm beyond vaginal mucosa. In the 14 patients treated for CIN-3 lesions, the mean total dose of HDR-ICR was 26.1 Gy (range 20-30). Six patients received HDR-ICR for VAIN-3 lesions with mean dose of 23.3 Gy (range 15-30). At follow-up (mean 90.5 months; range 13-153), 14 patients were alive and 6 had died owing to nonmalignant intercurrent disease. No patient developed recurrent disease. Rectal bleeding occurred in three patients, but this symptom subsided spontaneously. Moderate and severe vaginal reactions were noted in two patients, in whom the treatment had included the entire vagina.
HDR-ICR can be employed as the primary management strategy for postmenopausal women with CIN-3. In intraepithelial neoplasia involving the vaginal wall after hysterectomy, HDR-ICR should be considered as an alternative to total vaginectomy.
评估高剂量率腔内近距离放射治疗(HDR-ICR)对3级宫颈上皮内瘤变(CIN-3)和3级阴道上皮内瘤变(VAIN-3)患者的疗效。
这是一项对20例CIN-3(n = 14)或VAIN-3(n = 6)患者的回顾性分析,患者平均年龄61.9岁,在神奈川县癌症中心接受HDR-ICR治疗。2例伴有微浸润灶的CIN-3患者和另外11例CIN-3患者接受了针对宫颈病变的HDR-ICR治疗。6例子宫切除术后CIN-3患者因复发性或残留VAIN-3病变接受了HDR-ICR治疗。1例患者同时接受了针对CIN-3和VAIN-3病变的放射治疗。除1例患者外,所有这些患者均已绝经。
17例患者仅接受了HDR-ICR治疗,3例接受了外照射联合治疗。对于完整子宫,剂量在宫颈外口上方2 cm和子宫输卵管轴外侧2 cm处的A点计算。对于阴道残端病变,剂量在阴道顶端上方1 cm或阴道黏膜外1 cm处的一点计算。在14例接受CIN-3病变治疗的患者中,HDR-ICR的平均总剂量为26.1 Gy(范围20 - 30)。6例VAIN-3病变患者接受了HDR-ICR治疗,平均剂量为23.3 Gy(范围15 - 30)。随访时(平均90.5个月;范围13 - 153个月),14例患者存活,6例因非恶性并发疾病死亡。无患者出现复发性疾病。3例患者出现直肠出血,但该症状自行缓解。2例接受了包括整个阴道治疗的患者出现中度和重度阴道反应。
HDR-ICR可作为绝经后CIN-3女性的主要治疗策略。对于子宫切除术后累及阴道壁的上皮内瘤变,HDR-ICR应被视为全阴道切除术的替代方法。